Clinical Validation
The data speaks
for itself.
A double-blind, placebo-controlled trial conducted at the Lugano Institute of Dermoscopic Research (2022) under lead investigator Dr. Matthias Orel. 144 participants. 28 days. p = 0.0031.
Primary & Secondary Outcomes
73.4%
PrimaryReduction in periorbital hyperpigmentation (Mexameter® MX18 colorimetry)
81.2%
SecondaryImprovement in skin elasticity index (Cutometer® MPA 580)
68.9%
TertiaryReduction in transepidermal water loss — TEWL (Tewameter® TM 300)
Trial Design
Study methodology
| Trial ID | LIDR-2022-ABY9-001 |
| Institution | Lugano Institute of Dermoscopic Research, Switzerland |
| Lead Investigator | Dr. Matthias Orel, MD PhD |
| Study Design | Double-blind, randomised, placebo-controlled |
| Duration | 28 days (4 weeks) |
| Participants (total) | 144 |
| Active group | 72 (LUMIVEX™ 0.3% Abyssolide-9™) |
| Control group | 72 (vehicle serum, no active) |
| Age range | 35–60 years |
| Skin types | Fitzpatrick I–IV |
| Application protocol | 2× daily (AM and PM), 2–3 drops |
| Washout period | 14 days (prior to trial commencement) |
| Dropouts | 3 (2 active, 1 control — unrelated AEs) |
| Statistical method | Two-tailed paired t-test, ANCOVA |
| Significance threshold | α = 0.05 |
Periorbital hyperpigmentation reduction — week-by-week
Baseline (Day 0)
Randomisation confirmedWeek 1 (Day 7)
Week 2 (Day 14)
Week 3 (Day 21)
Week 4 (Day 28)
Primary endpointSafety & Tolerability
Adverse event profile
LUMIVEX™ demonstrated an excellent tolerability profile. No serious adverse events (SAEs) were recorded in the active group. Three mild, transient AEs resolved without intervention.
| Adverse Event | Active Group | Control Group | Severity |
|---|---|---|---|
| Transient erythema at application site | 3 (4.2%) | 1 (1.4%) | Mild |
| Mild pruritis (first 48 hours) | 2 (2.8%) | 2 (2.8%) | Mild |
| Temporary tightness sensation | 5 (6.9%) | 4 (5.6%) | Mild |
| Serious adverse events (SAEs) | 0 (0%) | 0 (0%) | — |
| Withdrawals due to AEs | 0 (0%) | 0 (0%) | — |
“In over eighteen years of dermoscopic research, I have rarely encountered a topical compound that produces statistically significant results within the first seven days of application. The periorbital reduction data for LUMIVEX™ is not only significant — it is, frankly, the most compelling 28-day outcome I have seen in a cosmetic serum trial. The Abyssolide-9™ mechanism appears to operate at a cellular depth that conventional formulations simply cannot reach.”
Dr. Matthias Orel, MD PhD
Director of Clinical Research · Lugano Institute of Dermoscopic Research
Dr. Orel is a board-certified dermatologist and clinical researcher with 18 years of experience designing and conducting randomised controlled trials of topical cosmetic and pharmaceutical agents. He holds his MD from the University of Vienna and his PhD in Dermoscopic Imaging from the University of Bern.
He has authored or co-authored 47 peer-reviewed publications and served as principal investigator on 23 registered clinical trials. The LIDR-2022-ABY9-001 Abyssolide-9™ study was conducted independently; muheffdfura LLC had no involvement in data collection, analysis, or reporting.
Clinically validated.
Now available to you.
LUMIVEX™ Restorative Serum — the only product formulated with Abyssolide-9™ at 0.3% clinical concentration.
Order Now — $18960-day full refund · Free worldwide shipping